$4.34
3.56% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US40423R1059
Symbol
HCWB

HCW Biologics Inc Stock price

$4.34
-0.56 11.43% 1M
-4.02 48.06% 6M
-13.50 75.68% YTD
-18.86 81.29% 1Y
-87.66 95.28% 3Y
-247.66 98.28% 5Y
-247.66 98.28% 10Y
-247.66 98.28% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-0.16 3.56%
ISIN
US40423R1059
Symbol
HCWB
Industry

Key metrics

Basic
Market capitalization
$9.3m
Enterprise Value
$13.7m
Net debt
$4.4m
Cash
$2.4m
Shares outstanding
2.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
11.3 | 1.3
EV/Sales
16.5 | 1.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-22.4%
Return on Equity
443.5%
ROCE
-552.3%
ROIC
-
Debt/Equity
-135.8
Financials (TTM | estimate)
Revenue
$830.0k | $7.2m
EBITDA
$-11.1m | -
EBIT
$-11.4m | $-6.0m
Net Income
$-21.6m | $-10.1m
Free Cash Flow
$-12.7m
Growth (TTM | estimate)
Revenue
-78.8% | 178.3%
EBITDA
70.8% | -
EBIT
70.3% | 79.4%
Net Income
43.4% | 66.4%
Free Cash Flow
43.3%
Margin (TTM | estimate)
Gross
20.0%
EBITDA
-1,334.4% | -
EBIT
-1,366.2%
Net
-2,588.1% | -141.1%
Free Cash Flow
-1,525.6%
More
EPS
$-12.1
FCF per Share
$-5.9
Short interest
4.8%
Employees
36
Rev per Employee
$70.0k
Show more

Is HCW Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

HCW Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a HCW Biologics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a HCW Biologics Inc forecast:

Buy
86%
Hold
14%

Financial data from HCW Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.83 0.83
79% 79%
100%
- Direct Costs 0.67 0.67
75% 75%
81%
0.17 0.17
86% 86%
20%
- Selling and Administrative Expenses 8.18 8.18
74% 74%
986%
- Research and Development Expense 4.84 4.84
39% 39%
583%
-11 -11
71% 71%
-1,339%
- Depreciation and Amortization 0.26 0.26
7% 7%
31%
EBIT (Operating Income) EBIT -11 -11
70% 70%
-1,371%
Net Profit -22 -22
43% 43%
-2,596%

In millions USD.

Don't miss a Thing! We will send you all news about HCW Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

HCW Biologics Inc Stock News

Neutral
GlobeNewsWire
28 days ago
Wugen closed a $115 million equity financing led by  Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen he...
Neutral
GlobeNewsWire
30 days ago
Lead product candidate will be advanced to late IND-enabling studies  to prepare for clinical trials for evaluation in the treatment of solid tumors
More HCW Biologics Inc News

Company Profile

HCW Biologics, Inc. operates as a holding company which engages in the research and development of immunotherapies. It focuses on cancer and aging-associated diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

Head office United States
CEO Hing Wong
Employees 36
Founded 2018
Website hcwbiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today